AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2023
Nov 3, 2023
32093_dirs_2023-11-03_48c6c404-ec4c-4e8e-b6c1-7c09c8cfe421.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2023-10-23
Reporting Person: Danahy Kevin Patrick (Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-10-23 | Stock Option (right to buy) | $3.96 | A | 130000 | Acquired | 2033-10-23 | Common Stock (130000) | Direct |
| 2023-11-01 | Stock Option (right to buy) | $3.96 | J | 130000 | Disposed | 2033-10-23 | Common Stock (130000) | Direct |
| 2023-11-01 | Stock Option (right to buy) | $4.38 | A | 460000 | Acquired | 2033-11-01 | Common Stock (460000) | Direct |
Footnotes
F1: The shares will vest in four equal annual installments on each of the first four annual anniversaries of the grant date, subject to the Reporting Person's continued service through each vesting date.
F2: Reporting Person was erroneously granted an option to acquire 130,000 shares on October 23, 2023, which option was cancelled by mutual agreement on November 1, 2023.
F3: 100% vesting upon the earlier of (i) the six (6) year anniversary of the grant date, and (ii) the 1-year anniversary of a Company change of control.